HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Interest Income
Income earned on cash, deposits, and investments held by the company.
HUTCHMED (China) LimitedNASDAQ: HCM
Interest Income · Q2 FY2025 · quarter ended Jun 2025
Interest income remains negative
Q2 FY2025 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $37.21M. Over 3 fiscal years it compounded at +73.4% a year.
Context
- Interest income amounted to 9.1% of revenue in FY2025, up 2.7 pp from a year earlier.
- Interest income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $9.3M.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 50.01M USD
- Year-over-year change
- +24.8%
- 4-year CAGR
- +121.5%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.01M | +24.8% |
| FY2024 | 2024-12-31 | 40.08M | +10.9% |
| FY2023 | 2023-12-31 | 36.15M | +276.5% |
| FY2022 | 2022-12-31 | 9.6M | +362.4% |
| FY2021 | 2021-12-31 | 2.08M | — |
Interest Income vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3.6% is the 4th highest of 8, against a peer median of -16.1%.
- Interest income amounts to 6.2% of revenue for HCM, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €420.15M EUR | — | +74.6% | 15.9% | |
| LTM Jun 2026 | $129.91M USD | — | -24.7% | 3.1% | |
| LTM Jun 2026 | $129.34M USD | +86.7% | — | 2.2% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥79.89M CNY | +111.1% | +101.8% | 14.3% |
| LTM Jul 2026 | $63.69M USD | -16.1% | +27.9% | 2.6% | |
| LTM Jun 2026 | $58M USD | +23.4% | +36.8% | 49.6% | |
| LTM Mar 2026 | $43.41M USD | -18.5% | +128.0% | 19.3% | |
| LTM Jun 2025 | $37.21M USD | +3.6% | +73.4% | 6.2% | |
| LTM Jun 2026 | $27.93M USD | -21.5% | +31.4% | 6.2% | |
| LTM Sep 2026 | $23.55M USD | -48.6% | +69.9% | 1.7% | |
| LTM Jun 2024 | $1.49M USD | — | -87.8% | 23.0% | |
| Peer median (excluding HCM) | — | -16.1% | +36.8% | 10.3% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 356.13M | 426.41M | 838M | 630.2M | 549.96M |
| Cost of Revenue | 258.23M | 311.1M | 384.45M | 348.88M | 337.24M |
| Gross Profit | 97.89M | 115.31M | 453.55M | 281.32M | 212.72M |
| Gross Margin | 27.5% | 27.0% | 54.1% | 44.6% | 38.7% |
| Research & Development | 207.45M | 267.59M | 303.06M | 213.37M | 164.15M |
| Selling, General & Admin | 127.13M | 136.11M | 133.18M | 112.91M | 103.3M |
| Operating Expenses | 426.21M | 523M | 436.23M | 321.93M | 267.45M |
| Depreciation & Amortization | 7.19M | 8.66M | 8.21M | 12.34M | 13.34M |
| EBITDA | (207.96M) | (401.11M) | 26.58M | (31.36M) | (41.38M) |
| EBITDA Margin | -58.4% | -94.1% | 3.2% | -5.0% | -7.5% |
| Operating Income | (328.32M) | (409.77M) | 18.38M | (43.71M) | (54.73M) |
| Operating Margin | -92.2% | -96.1% | 2.2% | -6.9% | -10.0% |
| Interest Income | 2.08M | 9.6M | 36.15M | 40.08M | 50.01M |
| Interest Expense | 592K | 652K | 759K | 2.87M | 2.87M |
| Other Income / Expenses | 173.19M | 51.52M | 87.23M | 89.07M | 577.45M |
| Income Before Tax | (155.33M) | (360.24M) | 105.6M | 45.36M | 522.72M |
| Pre-Tax Margin | -43.6% | -84.5% | 12.6% | 7.2% | 95.0% |
| Income Tax Expense | 11.92M | (283K) | 4.51M | 7.19M | 63.78M |
| Net Income | (194.65M) | (360.84M) | 100.78M | 37.73M | 458.12M |
| Net Margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
| EPS (Basic) | (1.25) | (2.15) | 0.60 | 0.22 | 2.65 |
| EPS (Diluted) | (1.25) | (2.15) | 0.60 | 0.22 | 2.60 |
| Weighted Avg Shares | 158.54M | 169.43M | 169.93M | 171.07M | 171.66M |
| Weighted Avg Shares (Diluted) | 158.54M | 169.43M | 173.84M | 174.57M | 174.58M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.